ReviewFuture oncology (London, England)2025
Molecular shifts in breast cancer following neoadjuvant chemotherapy: a prospective study and review of literature.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStandard clinical guidelines recommend evaluating Estrogen & progesterone Receptor (ER, PR), Human epidermal growth factor receptor-2 (HER-2), and Ki-67 in breast cancer biopsy samples. This study investigates the changes in molecular subtype following neoadjuvant chemotherapy (NACT) in breast cancer patients.
methodsPatients aged 18 to 65 years who underwent core needle biopsy before NACT and received at least four chemotherapy cycles were included in the study. Patients with inflammatory breast cancer, de novo metastatic or bilateral breast cancer, pregnancy, lactation, prior endocrine/radiation therapy, or achieved pathological complete response (pCR) were excluded. Molecular profiles (ER, PR, HER-2, Ki-67) were analyzed pre- and post-NACT.
resultsThe study involved 100 breast cancer patients with a median age of 51.78 years. 47% of patients underwent breast-conserving surgery (BCS), while 53% underwent modified radical mastectomy (MRM). Seventy-six percent of patients had tumors larger than 5 cm, and 72% presented with axillary lymph node metastasis. Initially, 90% and 89% of patients were ER, and PR positive, respectively, which decreased to 81% and 75% post-surgery. Ki67 expression showed a significant reduction following chemotherapy. Larger tumors and lymph node-positivity had significant changes in molecular subtypes.
conclusionThe study revealed significant alterations in ER, PR, HER-2, and Ki-67 levels post-NACT, prompting reassessment for tailored therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.